SCHEMBL22895601

SCHEMBL22895601

Bc1nc(Cl)nc(NC)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.43
YTHDC1 Q96MU7 11/20 0.42
PDE2A O00408 1/20 0.42
METAP2 P50579 1/20 0.34
METAP1 P53582 1/20 0.34
LMNA P02545 1/20 0.32
PGK1 P00558 1/20 0.32
CYP1A2 P05177 1/20 0.32
PDE4A P27815 1/20 0.32
CYP2C19 P33261 1/20 0.32
YTHDF3 Q7Z739 2/20 0.32
YTHDF1 Q9BYJ9 2/20 0.32
YTHDF2 Q9Y5A9 2/20 0.32
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
CACNA1B Q00975 1/20 0.31
APBA1 Q02410 1/20 0.31
ALDH1A1 P00352 1/20 0.30
ALOX15 P16050 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30733376 0.76 YTHDC1 (0.42) XDHYTHDC1PDE2AMETAP2METAP1
SCHEMBL20111045 0.76 YTHDC1 (0.42) XDHYTHDC1PDE2AMETAP2METAP1
SCHEMBL30712146 0.73 YTHDC1 (0.40) XDHYTHDC1PDE2AMETAP2METAP1
SCHEMBL16094334 0.70 YTHDC1 (0.61) XDHYTHDC1PDE2ACYP1A2PDE4A
SCHEMBL11360668 0.70 YTHDC1 (0.38) XDHYTHDC1PDE2ALMNACYP1A2
SCHEMBL22895988 0.67 ALDH1A1 (0.39) CYP1A2ALDH1A1ALOX15TSHR
SCHEMBL26794545 0.67 YTHDC1 (0.36) XDHYTHDC1PDE2APDE4A
SCHEMBL21230675 0.66 PDE2A (0.41) XDHYTHDC1PDE2ALMNACYP1A2
SCHEMBL25166582 0.65 YTHDC1 (0.46) XDHYTHDC1PDE2AMETAP2METAP1
SCHEMBL30329676 0.65 YTHDC1 (0.46) XDHYTHDC1PDE2AMETAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358958-B2 2022-06-14 US disclosed
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-05-06 US disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358958-B2 CDK2, CDK1, CDK6 XDH 2347/4885YTHDC1 4725/4885PDE2A 2743/4885
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK2, CCNK, CDK1 XDH 2602/4885YTHDC1 4714/4885PDE2A 3038/4885
US-10894788-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 XDH 2602/4885YTHDC1 4714/4885PDE2A 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.